CLAIMS

1. Use of a therapeutically effective amount of pemafibrate or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating moderate or severe hypertriglyceridemia in a subject in need thereof with severe renal impairment.

2. The use according to claim 1, wherein the therapeutically effective amount of pemafibrate or pharmaceutically acceptable salt thereof is from 0.2 to 1.0 mg, and wherein the medicament is to be administered orally per day.

3. The use according to claim 1, wherein the therapeutically effective amount of pemafibrate or pharmaceutically acceptable salt thereof is 0.4 mg, and wherein the medicament is to be administered orally per day.

4. The use of claim 1, wherein the patient is on high intensity statin therapy and aged ≥21 years with clinical ASCVD selected from a history of acute coronary syndrome or myocardial infarction, stable or unstable angina, coronary revascularization, stroke, transient ischemic attack [TIA] of atherosclerotic origin, or peripheral arterial disease or revascularization.

5. The use of claim 1, wherein the patient is on moderate or high intensity statin therapy and aged 40 to 75 years, inclusive, without clinical ASCVD but with type-2 diabetes and a history of LDL-C of 70 to 189 mg/dL, inclusive.

6. The use of claim 1, wherein the subject has a fasting baseline triglyceride level of greater than 1000 mg/dL (11.3 mmol/L).

7. Use of a therapeutically effective amount of pemafibrate or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for treating dyslipidemia in a renally impaired adult patient and a non-renally impaired adult patient, wherein the medicament is to be administered to both patients in the same daily dose at the initiation of therapy in the renally impaired and non-renally impaired patients.

8. The method of claim 7wherein the renally impaired patient is mildly to moderately renally impaired.

9. The method of claim 7wherein the renally impaired patient is severely renally impaired.

10. The use of claim 1 wherein the subject has an HDL-C concentration of less than 40 mg/dL and is on moderate to high intensity statin therapy.

11. The use of claim 1 wherein the subject has an HDL-C concentration of less than 40 mg/dL and an LDL-C concentration less than 70 mg/dL.

12. The use of claim 1 wherein the subject has an HDL-C concentration of less than 40 mg/dL and is on moderate to high intensity statin therapy and has a triglyceride concentration of from 200 to 500 mg/dL.

13. The use of claim 1 wherein the subject has an HDL-C concentration of less than 40 mg/dL and an LDL-C concentration less than 70 mg/dL and a triglyceride concentration of from 200 to 500 mg/dL.